Related Experiment Video

Updated: Jun 12, 2026

A Neonatal Rodent Model of Retroorbital Vein Injection
04:39

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

Propranolol in the management of periorbital infantile haemangioma

Jin Fong Cheng1, Glen A Gole, Timothy J Sullivan

  • 1Royal Children's Hospital, Brisbane, Queensland, Australia. jin_fong_cheng@nuhs.edu.sg

Clinical & Experimental Ophthalmology
|June 18, 2010
PubMed

Insights

Propranolol effectively reduced the size and color of infantile haemangiomas in children. This treatment also showed positive results in reducing astigmatism, with no significant side effects observed.

Area of Science:

  • Ophthalmology
  • Pediatric Oncology
  • Dermatology

Background:

  • Infantile haemangiomas are the most common orbital tumors in children.
  • Treatment is typically observational unless vision is threatened.
  • Alternative treatments like steroids and surgery carry inherent risks.

Purpose of the Study:

  • To review the safety and efficacy of propranolol for treating periorbital infantile haemangiomas.
  • To assess the impact of propranolol on lesion size, color, and associated astigmatism.

Main Methods:

  • Retrospective review of 10 patients treated by two ophthalmologists.
  • Data collected included lesion characteristics, treatment duration, and side effects.
  • Outcomes measured were changes in lesion size, color, and astigmatism.

Main Results:

  • All 10 patients showed reduced lesion color and size after treatment with propranolol.
  • Mean lesion size decreased from 756.7 to 543.2 mm² (P=0.075).
  • 60% of patients with astigmatism experienced successful reduction.

Conclusions:

  • Propranolol is a safe and effective treatment option for infantile haemangioma.
  • The study supports propranolol's use in managing periorbital haemangiomas.
  • No significant adverse events were reported in the patient cohort.
Abstract

More Related Videos

Periorbital Placement of a Laser Doppler Probe for Cerebral Blood Flow Monitoring Prior to Middle Cerebral Artery Occlusion in Rodent Models03:26

Periorbital Placement of a Laser Doppler Probe for Cerebral Blood Flow Monitoring Prior to Middle Cerebral Artery Occlusion in Rodent Models

Published on: November 22, 2024

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...